CONSULTING AGREEMENT     THIS AGREEMENT (the Agreement) is entered into this 5th
day, May, 2009, by and between Sanguine Corp. (hereinafter also SGUI or
Party) with offices located at 6 Green Street, Pasadena, CA and LKB Partners,
LLC whose primary offices are located at 3502 Scotts Lane, #1221, Philadelphia,
PA (hereinafter also  Consultant or Party) (collectively also the
Parties),  WHEREAS,  Sanguine Corp. is a biomedical device company with a proprietary
perfluorocarbon product called PHER-02 for use in multiple medical applications,
including as a contrast marker for MRI technology, that is in need of management
consulting work for its commercialization and is desirous of entering into a
consulting agreement with LKB Partners, LLC,  AND,  WHEREAS,  LKB Partners, LLC who is experienced in all matters regarding
financial and managerial implementation and oversight is desirous of entering
into a consulting agreement with Sanguine, Corp to serve as interim
Management,  NOW, THEREFORE,in consideration of the covenants of each
of the parties given to the other and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:   RECITALS  1. SERVICES  1.1 Effective as of the Effective Date, SGUI engages Consultant and
Consultant accepts an engagement with SGUI to render the consulting services for
SGUI as set forth herein Section 2.1 Services and Duties of Consultant.
 During the term of this Agreement, Consultant shall devote his time,
attention and abilities to the business of SGUI as may be necessary for the
exercise of the Consultants duties hereunder.  Nothing in this Agreement
shall be interpreted or construed as creating or establishing a relationship of
employer and/or employee between the Consultant and SGUI.    2. DUTIES  2.1 The Consultant shall devote reasonable time and effort to the
performance of this Agreement.  SGUI acknowledges that the Consultant shall
also be entitles to render services to others during the term hereof.
 Consultant will work with current SGUI management to assist in managing
the overall business of SGUI..  This will include, but not be limited to,
providing day-to-day oversight on all matters pertaining to SGUIs business and
endeavors, negotiation and execution of contracts, reporting on business matters
with the SGUI Board of Directors, managing cash flow and expenses, and any and
all other managerial and financial duties that are reasonable in scope.  3. TERM  3.1 The term of this Agreement shall be for a period of 24 months from
the Effective Date and may be extended by agreement of both Parties.  4. REMUNERATION  4.1 SGUI agrees to pay to the Consultant a total of 1,000,000 SGUI
common shares.  In addition, SGUI will grant Consultant options to purchase
up to 9.5 percent of the SGUI outstanding common shares at a price of .10
expiring on December 31, 2013.  The options will contain a provision that
will provide Consultant, in the event that within a three-year period commencing
from the execution date of this Agreement SGUI increases, for any reason, its
overall common share issuance, inclusive of issuance of a convertible security
or securities into SGUI common shares, the right to acquire up to 9.5 percent of
the increased SGUI common shares at the .10 price per share.  In addition,
the Consultant will be paid a monthly fee of $8,000 when, and if, affordable to
SGUI to do so.  In the event that SGUI cannot fulfill the $8,000 per month
fee, the Consultant may elect to receive the compensation in common shares.  4.2 SGUI will also reimburse Consultant for any and all related
expenses provided that receipts are presented to SGUI for those expenses.  5.0 CONFIDENTIALITY  5.1 The Consultant acknowledges SGUI will have reporting and
disclosure requirements under all applicable securities legislation.  The
Consultant covenants and agrees that it shall not any time, during or after the
termination of the Consultants engagement by SGUI, reveal, divulge, or make
known to any person (other than SGUI or its affiliates) or use for his own
accounts any confidential information that may be proprietary to SGUI.    5.2 The Consultant warrants and represents that he is duly qualified
to perform his duties hereunder, and further covenants this in performing his
duties will not engage in any activity that is in violation of any applicable
securities laws.  6.0 CHANGE OF CONTROL AND SALE OF SGUI  6.1 The Consultant acknowledges that in the event that there is a sale
of, or change of control of SGUI that this Agreement may be terminated, or
significantly amended and SGUI cannot guarantee that the Consultant will
continue his services.  In this event SGUI and Consultant will agree upon a
reasonable settlement.  7. NOTICES  7.1 Any notices delivered or received between either party shall be
deemed to be received:  (a) if it was delivered in person, on the day it was delivered; (b) if it was sent by facsimile transmission, on the day it was
delivered; (c) it was sent by mail, on the day it was received to the following
address:  LKB Partners, LLC Frank Marra, Pres 3502 Scotts Lane #1221 Philadelphia, PA 19129  Sanguine Corp. Tom Drees 6 Green Street Pasadena, CA  8. MODIFICATIONS
OF AGREEMENT  8.1 Any modification of this Agreement must be made in writing and
signed by both paries.  9. GOVERNING LAW  9.1 This Agreement shall be governed by and construed
in accordance with the laws of the State of
California.    10. ASSIGNABILITY  10.1 This Agreement may be assigned to a third party with notification
by Consultant to Sanguine within 15 days from the assigning date.  11. ENTIRE
AGREEMENT  11.1 The covenants in this Agreement shall be construed as an agreement
independent of any other provision in this Agreement.  The parties
acknowledge thats it is their intention that the provisions of this Agreement
are binding only to the extent that they may be lawful under existing applicable
laws and in the event that any provision of this Agreement is determined by a
court od law to be overly broad or unenforceable, the remaining valid provisions
shall remain in full force and effect.  This Agreement constitutes the
entire agreement between the parties hereto for the services to be performed as
herein described and the mutual covenants contained herein constitute due an
adequate consideration for the full performance by each party of its obligations
under this Agreement and any and all previous agreements, written or oral,
expressed or implied, between the parties or on their releases and forever
discharges the other of an from all manner of action, causes of action, claims
or demands whatsoever under or in respect of any agreement.  12. GENERAL
MATTERS  12.1 The waiver by any party hereto of a breach of any provision of
this Agreement shall not operate or be construed as a waiver of any subsequent
breach of the same or of any other provisions of this Agreement.  12.2 This Agreement shall be binding upon the parties hereto and shall
enure to the benefit of and shall be enforceable by each of the parties hereto
and their respective successors and assigns.   IN WITNESS WHEREOFthe parties hereto have executed this
Agreement as of the 5th day of May, 2009   Frank Marra, LKB Partners, LLC Tom Drees , Sanguine Corp.  /s/Frank Marra /s/Tom Drees